Charles River Laboratories Debt to Equity Ratio 2010-2024 | CRL

Current and historical debt to equity ratio values for Charles River Laboratories (CRL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Charles River Laboratories debt/equity for the three months ending March 31, 2024 was 0.73.
Charles River Laboratories Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-03-31 $4.51B $3.65B 1.24
2023-12-31 $4.59B $3.60B 1.28
2023-09-30 $4.30B $3.31B 1.30
2023-06-30 $4.52B $3.26B 1.39
2023-03-31 $4.59B $3.11B 1.47
2022-12-31 $4.62B $2.98B 1.55
2022-09-30 $4.75B $2.63B 1.80
2022-06-30 $4.88B $2.65B 1.84
2022-03-31 $4.46B $2.62B 1.71
2021-12-31 $4.49B $2.54B 1.77
2021-09-30 $4.63B $2.43B 1.90
2021-06-30 $4.40B $2.32B 1.89
2021-03-31 $3.62B $2.19B 1.66
2020-12-31 $3.37B $2.12B 1.59
2020-09-30 $3.31B $1.90B 1.74
2020-06-30 $3.48B $1.76B 1.98
2020-03-31 $3.55B $1.66B 2.14
2019-12-31 $3.06B $1.64B 1.87
2019-09-30 $3.05B $1.54B 1.98
2019-06-30 $3.17B $1.46B 2.17
2019-03-31 $2.53B $1.40B 1.80
2018-12-31 $2.54B $1.32B 1.92
2018-09-30 $2.54B $1.26B 2.02
2018-06-30 $2.68B $1.19B 2.26
2018-03-31 $1.86B $1.14B 1.63
2017-12-31 $1.88B $1.05B 1.80
2017-09-30 $1.84B $1.03B 1.80
2017-06-30 $1.81B $0.97B 1.87
2017-03-31 $1.82B $0.88B 2.07
2016-12-31 $1.87B $0.84B 2.23
2016-09-30 $1.82B $0.87B 2.08
2016-06-30 $1.93B $0.84B 2.30
2016-03-31 $1.32B $0.78B 1.68
2015-12-31 $1.33B $0.74B 1.81
2015-09-30 $1.32B $0.71B 1.87
2015-06-30 $1.18B $0.71B 1.67
2015-03-31 $1.18B $0.67B 1.77
2014-12-31 $1.20B $0.68B 1.77
2014-09-30 $1.17B $0.67B 1.73
2014-06-30 $1.19B $0.68B 1.76
2014-03-31 $0.95B $0.70B 1.36
2013-12-31 $0.99B $0.64B 1.54
2013-09-30 $0.98B $0.66B 1.49
2013-06-30 $0.97B $0.65B 1.49
2013-03-31 $0.97B $0.63B 1.54
2012-12-31 $0.98B $0.60B 1.63
2012-09-30 $0.97B $0.60B 1.61
2012-06-30 $0.98B $0.57B 1.74
2012-03-31 $1.00B $0.56B 1.81
2011-12-31 $1.03B $0.53B 1.96
2011-09-30 $1.04B $0.54B 1.93
2011-06-30 $1.12B $0.59B 1.89
2011-03-31 $1.18B $0.56B 2.09
2010-12-31 $1.05B $0.69B 1.52
2010-09-30 $1.04B $1.04B 1.00
2010-06-30 $0.76B $1.39B 0.55
2010-03-31 $0.80B $1.38B 0.58
2009-12-31 $0.83B $1.37B 0.60
2009-09-30 $0.84B $1.35B 0.62
2009-06-30 $0.87B $1.28B 0.68
2009-03-31 $0.87B $1.22B 0.71
Sector Industry Market Cap Revenue
Medical Medical Services $11.347B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $116.504B 14.20
Cencora (COR) United States $44.729B 17.44
ICON (ICLR) Ireland $27.407B 25.88
DiDi Global (DIDIY) China $17.692B 0.00
CochLear (CHEOY) Australia $14.645B 0.00
Avantor (AVTR) United States $14.380B 21.17
Viatris (VTRS) United States $13.693B 4.09
Revvity (RVTY) United States $13.578B 23.82
Natera (NTRA) United States $13.081B 0.00
Medpace Holdings (MEDP) United States $11.070B 33.61
EUROFINS SCIENT (ERFSF) Luxembourg $9.854B 0.00
Solventum (SOLV) United States $9.782B 0.00
Sonic Healthcare (SKHHY) Australia $8.268B 0.00
HealthEquity (HQY) United States $6.856B 44.02
Bausch + Lomb (BLCO) Canada $5.992B 23.99
Organon (OGN) United States $5.519B 5.23
Doximity (DOCS) United States $5.235B 36.66
PACS (PACS) United States $5.163B 0.00
Life Times (LTH) United States $4.191B 43.92
Sotera Health (SHC) United States $3.773B 18.51
Surgery Partners (SGRY) United States $3.602B 32.95
GoodRx Holdings (GDRX) United States $3.343B 127.29
Agilon Health (AGL) United States $2.904B 0.00
Progyny (PGNY) United States $2.691B 46.33
AMN Healthcare Services Inc (AMN) United States $2.272B 9.00
BrightSpring Health Services (BTSG) United States $2.085B 0.00
Premier (PINC) United States $2.083B 8.91
Alignment Healthcare (ALHC) United States $1.824B 0.00
Teladoc Health (TDOC) United States $1.577B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.467B 0.00
Establishment Labs Holdings (ESTA) $1.321B 0.00
CareDx (CDNA) United States $0.990B 0.00
Embecta (EMBC) United States $0.935B 6.36
GeneDx Holdings (WGS) United States $0.869B 0.00
InnovAge Holding (INNV) United States $0.840B 0.00
Pediatrix Medical (MD) United States $0.646B 6.86
Auna S.A (AUNA) Luxembourg $0.638B 0.00
Sharecare (SHCR) United States $0.500B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.497B 0.00
Enhabit (EHAB) United States $0.488B 48.65
Sonida Senior Living (SNDA) United States $0.420B 0.00
QDM (QDMI) Hong Kong, SAR China $0.353B 9.24
DocGo (DCGO) United States $0.337B 18.44
ModivCare (MODV) United States $0.337B 6.30
LifeMD (LFMD) United States $0.292B 0.00
MultiPlan (MPLN) United States $0.289B 0.00
Sera Prognostics (SERA) United States $0.260B 0.00
Beauty Health (SKIN) United States $0.230B 0.00
Ascend Wellness Holdings (AAWH) United States $0.206B 0.00
Biodesix (BDSX) United States $0.189B 0.00
So-Young (SY) China $0.098B 47.50
Pono Capital Two (PTWO) United States $0.072B 0.00
NeueHealth (NEUE) United States $0.044B 5.88
Oncology Institute (TOI) United States $0.041B 0.00
Co-Diagnostics (CODX) United States $0.041B 0.00
IceCure Medical (ICCM) Israel $0.038B 0.00
Nutex Health (NUTX) United States $0.037B 0.00
OncoCyte (OCX) United States $0.027B 0.00
SeaStar Medical Holding (ICU) United States $0.024B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.023B 0.00
Singular Genomics Systems (OMIC) United States $0.020B 0.00
KindlyMD (KDLY) $0.018B 0.00
TRxADE HEALTH (MEDS) United States $0.017B 0.00
BIMI Holdings (BIMI) United States $0.016B 0.00
BioNexus Gene Lab (BGLC) $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.005B 0.00
OpGen (OPGN) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Singapore $0.003B 0.00
Aclarion (ACON) United States $0.003B 0.00
Assure Holdings (IONM) United States $0.001B 0.00